BioSenic SA is a biotechnology company with extensive scientific and clinical experience in the field of orthopedics and regenerative therapies, specializing in the clinical development of therapies for bone and cartilage repair. BioSenic SA still holds stakes in its clinical assets ALLOB and JTA, but is now focusing on joint development with 4Moving Biotech of a GLP-1-based disease-modifying therapy for veterinary use, particularly for recovery after ligament surgery in dogs. BioSenic SA is also focusing on other potential new partnerships.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	1.5M 1.72M 1.41M 1.29M 2.42M 164M 2.42M 16.94M 6.54M 83.88M 6.45M 6.31M 270M	P/E 2023	-0.29x	P/E 2024	-0.28x
Enterprise Value	28.84M 33M 27.1M 24.73M 46.42M 3.15B 46.43M 325M 126M 1.61B 124M 121M 5.19B	EV / Sales 2023	113x	EV / Sales 2024	286x
Free-Float	85.86%	Yield 2023 *	-	Yield 2024	-

28/10/25	BioSenic S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
03/10/25	BioSenic S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
29/09/25	Bone Therapeutics SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
28/10/24	BioSenic S.A. Announces Executive Changes	CI
30/09/24	BioSenic S.A. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
30/09/24	Bone Therapeutics SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI
17/09/24	BioSenic Deputy CEO Steps Down	MT
17/09/24	Véronique Pomi-Schneiter Step Down as BioSenic's Deputy CEO	CI
14/08/24	BioSenic Unit Secures European Patent for Multiple Sclerosis Treatment	MT
14/08/24	Medsenic, Subsidiary of Biosenic Receives the Intention to Grant Key European Patent from European Patent Office	CI
13/08/24	BioSenic Grants of A Key Patent by the Japan Patent Office to Expand Protection of the Arsenic Trioxide Platform	CI
18/07/24	Biosenic Releases New In-Depth Analysis of Its Positive Phase 2 Clinical Data for Optimal Administration Scheme for Its Next Late-Stage Trial of Arsenic Trioxide Targeting Cgvhd	CI
05/07/24	BioSenic Seeks US Patent Extension for Sepsis Drug	MT

12-14	BioSenic : Report from Auditor on ESEF format 2024 Annual Report	PU
25/09/25	BioSenic : appoints CarKath SRL, represented by Mr Eric Halioua, as chairman of the board of directors	PU
29/08/25	BioSenic : provides an update on the preparation of the annual accounts and annual report for the financial year ending on 31 December 2024	PU
04/08/25	BioSenic : announces the homologation by the Enterprise Court of BioSenic's amicable agreements with five main creditors to restructure over €22 million of debt and appointment of two new independent directors	PU
01/07/25	BioSenic : announces partnership with 4Moving Biotech and secures its financing.	PU

05-07	BioSenic : Procuration pour l'actionnaire
05-07	BioSenic : Rapport annuel 2025
05-07	BioSenic : Communiqué de Presse - Convocation à l'Assemblée Générale Ordinaire
04-28	BioSenic : BIOS PR 2026 avril Denominator FR20260428
04-12	BioSenic : annonce l'émission de droits de souscription au bénéfice de membres du conseil d'administration

Director	Title	Age	Since
Jean-Luc Vandebroek BRD	Director/Board Member	55	01/01/2022
Eric Halioua CHM	Chairman	-	01/09/2025
Virginie Miath BRD	Director/Board Member	-	29/01/2026

BioSenic SA Stock OTC Markets

Stocks

BNZPF

BE0974280126

Pharmaceuticals

Valuation: BioSenic SA

Latest news: BioSenic SA

Analysts' recommendations: BioSenic SA

Press Releases: BioSenic SA

News in other languages: BioSenic SA

Managers and Directors: BioSenic SA

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOSENIC SA	-.--%	-.--%	-	-	1.5M
ELI LILLY AND COMPANY	+0.45%	+2.80%	+55.61%	+112.70%	1,038B
JOHNSON & JOHNSON	-0.10%	+1.08%	+52.78%	+66.52%	649B
ABBVIE INC.	+0.28%	+1.31%	+19.21%	+72.85%	467B
ROCHE HOLDING AG	-0.19%	+0.75%	+37.34%	+45.03%	355B
NOVARTIS AG	+0.28%	+2.23%	+19.12%	+25.62%	269B
ASTRAZENECA PLC	+0.89%	+4.26%	+12.10%	+16.41%	260B
AMGEN INC.	+4.34%	+7.53%	+43.74%	+52.27%	213B
NOVO NORDISK A/S	-0.46%	-7.70%	-33.40%	-59.71%	176B
GILEAD SCIENCES, INC.	+1.40%	+4.28%	+33.82%	+102.83%	187B
Average	+0.73%	+1.04%	+26.70%	+48.28%	401.68B
Weighted average by Cap.	+0.63%	+1.47%	+36.59%	+66.72%

	2023	2024
Net sales	336K 384K 316K 288K 541K 36.76M 541K 3.79M 1.46M 18.77M 1.44M 1.41M 60.51M	102K 117K 95.87K 87.48K 164K 11.16M 164K 1.15M 444K 5.7M 438K 429K 18.37M
Net income	-28.78M -32.93M -27.05M -24.68M -46.32M -3.15B -46.33M -325M -125M -1.61B -124M -121M -5.18B	-4.77M -5.46M -4.48M -4.09M -7.68M -522M -7.68M -53.78M -20.75M -266M -20.49M -20.04M -859M
Net Debt	28.04M 32.09M 26.35M 24.05M 45.14M 3.07B 45.15M 316M 122M 1.57B 121M 118M 5.05B	27.34M 31.28M 25.69M 23.45M 44M 2.99B 44.01M 308M 119M 1.53B 117M 115M 4.92B